



Stony Brook
Medicine



Stony Brook
Children's

Insights into DNA damage response signaling from an oncovirus

*Sumita Bhaduri-McIntosh, M.D., Ph.D.
Pediatric Infectious Diseases &
Molecular Genetics and Microbiology*

Cellular metabolism


Ionizing radiation

Replication errors

UV light

Chemical exposures

Cellular/Viral oncogenes



Cell cycle
checkpoint activation

Immune
stimulation


Antiviral functions

Apoptosis
Senescence
Aging

DNA repair

DNA
replication

Transcriptional
program activation




Circumventing DDR during oncogene-driven cell proliferation

- For oncogenes to successfully drive cell proliferation and cancer, DNA damage checkpoint barriers need to be overridden
- Mechanisms of DDR attenuation: inherited versus sporadic cancers
- STAT3 – transcription factor
 - frequently activated by growth factors and cytokines
 - prosurvival, angiogenesis, metastasis
 - constitutively active in many human cancers
 - precise contribution to tumorigenesis unknown

Does/Can STAT3 mediate DDR suppression during the initial rounds of oncogene-driven cell proliferation?




Epstein-Barr virus (EBV)



- Post-transplant lymphomas, AIDS-lymphomas, Burkitt lymphoma, NPC, Hodgkin lymphomas, T/NK cell lymphomas, gastric carcinomas
- Oncogenic human gammaherpesvirus
 - co-evolved with humans, infects nearly everyone
 - excellent means to uncover fundamental cellular processes
 - encodes several oncoproteins, drives cellular DNA replication, causes cellular DNA damage
 - post-transplant lymphomas develop within weeks of infection
 - primary human B cells + EBV.....cell lines in 2 weeks
 - STAT3 constitutively active in EBV-related cancers



Does STAT3 mediate DDR suppression during the initial rounds of EBV oncogene-driven cell proliferation?

EBV infection results in early STAT3 activation and increased expression




Inhibition of STAT3 results in fewer EBV⁺ cells



Day 4 Culture







STAT3 is necessary for outgrowth of cell lines




STAT3 is necessary for survival of LMP1⁺ cells





AG490 inhibits STAT3 and its targets including pro-survival genes




STAT3 is necessary for proliferation past the S phase
.....*or impairment of STAT3 causes S phase delay/arrest*



STAT3 is necessary for proliferation past the S phase
.....*or impairment of STAT3 causes S phase delay/arrest*




STAT3 blocks signalling downstream of ATR



STAT3 suppresses pChk1 levels

Day 4 Culture




Healthy LCL AD-HIES LCL




Healthy LCL

LCL 1 LCL 2

siRNA Sc STAT3 Sc STAT3






Proliferating EBV-infected cells in vivo show high STAT3 but low pChk1







STAT3 functions via Chk1 to promote progression of EBV-infected cells past the S phase

AD-HIES LCL




Cells with functional STAT3 demonstrate loss of nuclear Claspin



Day 4




EBV infection in the presence of STAT3 results in caspase 7 activation




Caspase inhibition causes Claspin recovery and failure of EBV-mediated growth transformation



Inhibition of Caspase 7 (but not Caspase 6) causes recovery of Claspin and pChk1



Model for DDR suppression during the initial rounds of EBV-oncogene-driven cell proliferation



Summary

- Link STAT3 to DDR suppression during oncogene-driven cell proliferation
- A newly discovered function for STAT3 (constitutively active in most cancers)
- STAT3 mediated relaxation of the intra-S phase checkpoint is a previously unknown mechanism for genomic instability
- Caspase 7 in a non-apoptotic role
- STAT3, a major transcription factor, is central to cell proliferation – implications beyond EBV infection and tumorigenesis

Contributions

Siva Koganti, Ph.D.

Xiaofan Li, Ph.D.

Eric Burton, B.S.

Sal Spadaro, B.S., B.A.

Erik Hill, Ph.D.

Shane McAllister, M.D., Ph.D.

Joyce Hui-Yuen, M.D., M.S.

Sameer Lapsia, M.D.

Cynthia Megyola, M.S.

Funding:

NIAID

NICHD

Charles Hood Foundation

Yale Center for Clinical Investigation

American Academy of Pediatrics

Stony Brook Research Foundation

Collaborators:

Alexandra Freeman, M.D.

Steven Holland, M.D.

NIAID, NIH, USA

Jizu Zhi, Ph.D.

Stony Brook University, USA

Paul Farrell, Ph.D.

Imperial College, UK

Benjamin Gardner, M.D.

Yale University, USA

Stuart Tangye, Ph.D.

Garvan Institute, Australia

Friedrich Grässer, Ph.D.

**Universitätsklinikum des Saarlandes,
Germany**